The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris therapeutics | Common | 00461U105 | 77,415 | 4,191,397 | SH | SOLE | 0 | 0 | 4,191,397 | ||
| Advanced Accelerator Applications S.A. | Common | 00790T100 | 13,781 | 455,798 | SH | SOLE | 0 | 0 | 455,798 | ||
| Agile Therapeutics, Inc. | Common | 00847L100 | 15,372 | 2,019,955 | SH | SOLE | 0 | 0 | 2,019,955 | ||
| Aimmune Therapeutics, Inc. | Common | 00900T107 | 8,256 | 763,009 | SH | SOLE | 0 | 0 | 763,009 | ||
| Akari Therapeutics Plc | ADR | 00972G108 | 7,121 | 527,842 | SH | SOLE | 0 | 0 | 527,842 | ||
| Ascendis Pharma | ADR | 04351P101 | 23,446 | 1,766,832 | SH | SOLE | 0 | 0 | 1,766,832 | ||
| Capnia, Inc. | Common | 14066L105 | 8,650 | 7,456,984 | SH | SOLE | 7,456,984 | 0 | 0 | ||
| Capnia, Inc. | Warrant | 14066L113 | 245 | 943,858 | SH | SOLE | 943,858 | 0 | 0 | ||
| Carbylan Therapeutics | Common | 141384107 | 2,775 | 4,204,562 | SH | SOLE | 0 | 0 | 4,204,562 | ||
| Codexis, Inc. | Common | 192005106 | 22,460 | 5,573,319 | SH | SOLE | 0 | 0 | 5,573,319 | ||
| Dynavax Technologies Corporation | Common | 268158201 | 5,246 | 359,828 | SH | SOLE | 0 | 0 | 359,828 | ||
| Eiger BioPharmaceuticals | Common | 28249U105 | 31,704 | 1,599,591 | SH | SOLE | 1,599,591 | 0 | 0 | ||
| MEI Pharma, Inc. | Common | 55279B202 | 1,498 | 1,101,129 | SH | SOLE | 0 | 0 | 1,101,129 | ||
| Minerva Neurosciences, Inc. | Common | 603380106 | 2,042 | 200,000 | SH | SOLE | 0 | 0 | 200,000 | ||
| Nabriva Therapeutics AG | ADR | 62957M104 | 23,638 | 3,151,700 | SH | SOLE | 3,151,700 | 0 | 0 | ||
| Ocera Therapeutics, Inc. | Common | 67552A108 | 291 | 153,331 | SH | SOLE | 0 | 0 | 153,331 | ||
| Palatin Technologies, Inc. | Common | 696077403 | 103 | 234,909 | SH | SOLE | 0 | 0 | 234,909 | ||
| ProNAi Therapeutics, Inc. | Common | 74346L101 | 4,852 | 2,438,270 | SH | SOLE | 0 | 0 | 2,438,270 | ||
| Regenxbio Inc. | Common | 75901B107 | 7,924 | 990,449 | SH | SOLE | 0 | 0 | 990,449 | ||
| ReVance Therapeutics, Inc. | Common | 761330109 | 1,052 | 77,373 | SH | SOLE | 0 | 0 | 77,373 | ||
| Sagent Pharmaceuticals, Inc. | Common | 786692103 | 97,301 | 6,495,416 | SH | SOLE | 0 | 0 | 6,495,416 | ||
| Trevena, Inc. | Common | 89532E109 | 10,886 | 1,728,000 | SH | SOLE | 0 | 0 | 1,728,000 | ||
| Zosano Pharma Corp | Common | 98979H103 | 125 | 98,515 | SH | SOLE | 0 | 0 | 98,515 | ||